Last reviewed · How we verify
NCT06908135: ActivatePD
Effects of an Independent Walking Program With Walking Poles in People With Parkinson Disease
NA trial testing Independent walking program using walking poles in Parkinson Disease in 11 participants. Terminated before completion.
30 June 2025
Quick facts
| Lead sponsor | Pacific Northwest University of Health Sciences |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 29 March 2025 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Independent walking program using walking poles
- Independent walking program without walking poles
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Pacific Northwest University of Health Sciences
Who can join
Eligibility, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
* Study Purpose: The purpose of the study is to compare changes in activity levels and walking in people with Parkinson disease after an 8-week independent walking program with or without using walking poles. * Major parts of the Study: Before the walking program: You will wear an activity sensor on your upper leg for one week to track activity levels. Measurements will be taken of you while you are walking. If you are placed in the walking pole group, you will be trained on how to use walking poles. Independent walking program: You will be asked to walk at least 3 times each week for 8 weeks and keep a log of your walking. If you are in the walking pole group, you will walk with the poles. After the walking program: Your walking measurements will be collected as before the walking program. You will wear an activity sensor for one week.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06908135
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Pacific Northwest University of Health Sciences trials
Trials by the same sponsor.
- NCT06576817 — High-intensity Interval Circuit Training in People With Parkinson Disease · NA · completed
- NCT06214455 — Diet and Fasting for Long COVID · NA · completed
- NCT06820684 — Inflammatory Response to OMT · NA · completed
- NCT03975439 — Chronic Kidney Disease and Cardiovascular Disease Risk Assessment · withdrawn
- NCT04082585 — Total Health Improvement Program Research Project · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06908135 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pacific Northwest University of Health Sciences
- Last refreshed: 30 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06908135.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing